101 – 110 of 123
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2004
-
Mark
Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma
(
- Contribution to journal › Article
-
Mark
High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation.
(
- Contribution to journal › Article
- 2003
-
Mark
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
(
- Contribution to journal › Article
-
Mark
Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
(
- Contribution to journal › Article
-
Mark
A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences.
(
- Contribution to journal › Article
-
Mark
Radiation therapy dose delivery
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
(
- Contribution to journal › Article
- 2002
-
Mark
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
(
- Contribution to journal › Article
-
Mark
Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy.
(
- Contribution to journal › Article
-
Mark
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase - a report from the Swedish CML Group
(
- Contribution to journal › Article